TWI486183B - 含有奧美沙坦酯製劑之臭味防止方法 - Google Patents
含有奧美沙坦酯製劑之臭味防止方法 Download PDFInfo
- Publication number
- TWI486183B TWI486183B TW102113345A TW102113345A TWI486183B TW I486183 B TWI486183 B TW I486183B TW 102113345 A TW102113345 A TW 102113345A TW 102113345 A TW102113345 A TW 102113345A TW I486183 B TWI486183 B TW I486183B
- Authority
- TW
- Taiwan
- Prior art keywords
- odor
- olmesartan medoxomil
- layer
- density polyethylene
- low density
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 40
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 title claims description 31
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 title claims description 31
- 229960001199 olmesartan medoxomil Drugs 0.000 title claims description 31
- 239000003814 drug Substances 0.000 title description 6
- 239000010410 layer Substances 0.000 claims description 97
- 238000001179 sorption measurement Methods 0.000 claims description 48
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 43
- 229910021536 Zeolite Inorganic materials 0.000 claims description 40
- 239000010457 zeolite Substances 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 39
- -1 polypropylene Polymers 0.000 claims description 29
- 239000003463 adsorbent Substances 0.000 claims description 28
- 239000004743 Polypropylene Substances 0.000 claims description 25
- 229920001155 polypropylene Polymers 0.000 claims description 25
- 239000000758 substrate Substances 0.000 claims description 21
- 229920001684 low density polyethylene Polymers 0.000 claims description 20
- 239000004702 low-density polyethylene Substances 0.000 claims description 20
- 238000004806 packaging method and process Methods 0.000 claims description 19
- 229920000092 linear low density polyethylene Polymers 0.000 claims description 18
- 239000004707 linear low-density polyethylene Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000002209 hydrophobic effect Effects 0.000 claims description 11
- 239000000565 sealant Substances 0.000 claims description 11
- 239000012790 adhesive layer Substances 0.000 claims description 8
- 239000004800 polyvinyl chloride Substances 0.000 claims description 7
- 240000006394 Sorghum bicolor Species 0.000 claims description 6
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 6
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 6
- 239000006096 absorbing agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 235000019645 odor Nutrition 0.000 description 53
- 239000005022 packaging material Substances 0.000 description 41
- 239000000463 material Substances 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- 239000011347 resin Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 125000002541 furyl group Chemical group 0.000 description 9
- 229910052782 aluminium Inorganic materials 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
- 238000003475 lamination Methods 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 239000005038 ethylene vinyl acetate Substances 0.000 description 6
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000004576 sand Substances 0.000 description 5
- 229920005992 thermoplastic resin Polymers 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 4
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000009820 dry lamination Methods 0.000 description 4
- 229920006242 ethylene acrylic acid copolymer Polymers 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 239000005033 polyvinylidene chloride Substances 0.000 description 4
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229920005648 ethylene methacrylic acid copolymer Polymers 0.000 description 3
- 229920005680 ethylene-methyl methacrylate copolymer Polymers 0.000 description 3
- 238000011990 functional testing Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229910000420 cerium oxide Inorganic materials 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920006225 ethylene-methyl acrylate Polymers 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229920000554 ionomer Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009816 wet lamination Methods 0.000 description 2
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- ULVDFHLHKNJICZ-QCWLDUFUSA-N (4e)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1COC(C=C1)=CC=C1CO\N=C(/CCC(O)=O)C1=CC=CC=C1 ULVDFHLHKNJICZ-QCWLDUFUSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- FAFVVBJEQCPDIA-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 FAFVVBJEQCPDIA-UHFFFAOYSA-N 0.000 description 1
- TXIIZHHIOHVWJD-UHFFFAOYSA-N 2-[7-(2,2-dimethylpropanoylamino)-4,6-dimethyl-1-octyl-2,3-dihydroindol-5-yl]acetic acid Chemical compound CC(C)(C)C(=O)NC1=C(C)C(CC(O)=O)=C(C)C2=C1N(CCCCCCCC)CC2 TXIIZHHIOHVWJD-UHFFFAOYSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 1
- BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- JFKJWWJOCJHMGV-WCCKRBBISA-N Ethyl L-cysteine hydrochloride Chemical compound Cl.CCOC(=O)[C@@H](N)CS JFKJWWJOCJHMGV-WCCKRBBISA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- OKJHGOPITGTTIM-DEOSSOPVSA-N Naveglitazar Chemical compound C1=CC(C[C@H](OC)C(O)=O)=CC=C1OCCCOC(C=C1)=CC=C1OC1=CC=CC=C1 OKJHGOPITGTTIM-DEOSSOPVSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229950004646 azelnidipine Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 1
- 229960004272 bucillamine Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940061262 ethyl cysteine hydrochloride Drugs 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- OGVXWEOZQMAAIM-UHFFFAOYSA-N hydron;2-methylaniline;chloride Chemical compound Cl.CC1=CC=CC=C1N OGVXWEOZQMAAIM-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000005001 laminate film Substances 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 229950003510 pactimibe Drugs 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- LHYPLJGBYPAQAK-UHFFFAOYSA-M sodium;pentanoate Chemical compound [Na+].CCCCC([O-])=O LHYPLJGBYPAQAK-UHFFFAOYSA-M 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 238000009823 thermal lamination Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229950001089 todralazine Drugs 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
- B01J20/16—Alumino-silicates
- B01J20/18—Synthetic zeolitic molecular sieves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
- B65D81/267—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants the absorber being in sheet form
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mechanical Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Composite Materials (AREA)
- Inorganic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Wrappers (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Description
本發明係相關於含有臭味吸附劑之包裝材及包裝醫藥品之壓泡包裝或泡罩包裝。
先前包裝醫藥品時,廣泛使用壓泡包裝(PTP)或泡罩包裝,惟醫藥品中有些具有製劑特有之臭味,實施壓泡包裝或泡罩包裝的醫療設備之調劑工作人員,時常對其臭味感到不舒服感。且服用者從壓泡包裝或泡罩包裝取出錠劑時或服用時,亦對其臭味感到不舒服感。該類製劑導致服用者的順應性降低且影響商品價值。
醫藥品的壓泡包裝或泡罩包裝之包裝型態中,吸附由製劑散發的臭味之方法,係以高氣體遮蔽性的鋁層壓薄片使壓泡包裝或泡罩包裝密閉(以下稱為「枕包裝」),將臭味吸附劑裝入其中,吸收由壓泡包裝或泡罩包裝釋出些微的臭味之方法。惟,為確保製劑的衛生性、長期間的安定性,通常壓泡包裝或泡罩包裝係選擇氣密性較高的包裝材,因此臭味物質殘留於壓泡包裝或泡罩包裝的袋中,抑制臭味之效果不足。雖有使沸石均勻分散混合於薄膜材之除臭薄膜材(特開平11-35077號公報),惟無任何有關於為包裝含有本發明的特定藥劑的製劑之包裝材。
專利文獻1:特開平11-35077號公報
本發明的目的係提供一種吸附由含有奧美沙坦酯(Olmestartan Medoxomil)或2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑之製劑產生的臭味物質之包裝材。
本發明者等為完成上述目的而致力研究之結果,發現使包裝材含有臭味吸附劑,和包裝材吸附由含有奧美沙坦酯或2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑產生的臭味物質而降低其氣體濃度,藉此防止或降低從包裝體取出製劑時的臭味感覺,可減輕不舒服感而完成本發明。
亦即,本發明係提供(1)一種包裝材,其特徵係為包裝含有奧美沙坦酯的製劑用之包裝材,且含有臭味吸附劑,(2)如第(1)項之包裝材,其中臭味吸附劑係選自於物理吸附劑及化學吸附劑之化合物中的1種或2種以上,(3)如第(1)項之包裝材,其中臭味吸附劑係選自於合成沸石、活性碳之化合物中的1種或2種以上,(4)如第(1)項之包裝材,其中臭味吸附劑係合成沸石13X,(5)如第(1)項之包裝材,其中臭味吸附劑係疏水性沸石,(6)如第(1)項之包裝材,其中臭味吸附劑係對合成沸石13X施予疏水性處理之疏水性沸石,
(7)如第(1)項之包裝材,其中臭味吸附劑係高矽沸石,(8)如第(1)至(7)項中任一項之包裝材,其中包裝材係多層薄膜,(9)如第(8)項之包裝材,其中多層薄膜係具有含臭味吸附劑的吸附層及基材層,(10)如第(9)項之包裝材,其中在吸附層和基材層之間更具有黏附層,(11)如第(9)或(10)項之包裝材,其中在與基材層相對之吸附層側,更具有密封膠層,(12)如第(9)至(11)項中任一項之包裝材,其中在與基材層接觸之吸附層側,更具有外層,(13)如第(9)至(12)項中任一項之包裝材,其中吸附層係含有選自於低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯、離子鍵聚合物、乙烯丙烯酸共聚物、乙烯甲基丙烯酸共聚物、乙烯醋酸乙烯酯共聚物、乙烯丙烯酸乙烯酯共聚物、乙烯丙烯酸甲酯共聚物、乙烯甲基丙烯酸甲酯共聚物之化合物中的1種或2種以上,(14)如第(9)至(12)項中任一項之包裝材,其中吸附層係含有選自於低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯之化合物中的1種或2種以上,(15)如第(9)至(12)項中任一項之包裝材,其中吸附層係含有低密度聚乙烯,(16)如第(9)至(15)項中任一項之包裝材,其中基材層係含有選自於聚氯乙烯、無延展聚丙烯、聚丙烯、聚偏
二氯乙烯、聚三氟化氯乙烯、環狀烯烴共聚物之化合物中的1種或2種以上,(17)如第(9)至(15)項中任一項之包裝材,其中基材層係含有聚氯乙烯,(18)如第(10)至(17)項中任一項之包裝材,其中黏附層係含有選自於低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯之化合物中的1種或2種以上,(19)如第(10)至(17)項中任一項之包裝材,其中黏附層係含有低密度聚乙烯,(20)如第(11)至(19)項中任一項之包裝材,其中密封膠層係含有選自於低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯之化合物中的1種或2種以上,(21)如第(11)至(19)項中任一項之包裝材,其中密封膠層係含有直鏈狀低密度聚乙烯,(22)如第(12)至(21)項中任一項之包裝材,其中外層係含有選自於低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯的化合物中之1種或2種以上,(23)如第(12)至(21)項中任一項之包裝材,其中外層係含有直鏈狀低密度聚乙烯,(24)一種壓泡包裝或泡罩包裝,其係使用如第(1)至(23)項中任一項之包裝材,(25)一種壓泡包裝或泡罩包裝,其係於容器的附袋式薄片(pocket sheet)使用如第(1)至(23)項中任一項之包裝材,
(26)如第(24)或(25)項之壓泡包裝或泡罩包裝,其係包裝含有奧美沙坦酯之製劑,(27)一種含有奧美沙坦酯之製劑,其係以如第(1)至(23)項中任一項之包裝材進行包裝,(28)一種含有奧美沙坦酯之製劑,其係以如第(24)或(25)項之壓泡包裝或泡罩包裝進行包裝,(29)一種含有奧美沙坦酯製劑之臭味防止方法,其特徵係以如第(1)至(23)項中任一項之包裝材進行包裝,(30)一種含有奧美沙坦酯製劑之臭味防止方法,其特徵係以如第(24)或(25)項之壓泡包裝或泡罩包裝進行包裝。
又從其他觀點,本發明係提供(31)一種包裝材,其係在第(1)至(23)項中,適用於以含有2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑的製劑取代含有奧美沙坦酯的製劑之包裝材,(32)一種壓泡包裝或泡罩包裝,其係在第(24)至(26)項中,適用於以含有2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑的製劑取代含有奧美沙坦酯的製劑之壓泡包裝或泡罩包裝,(33)一種製劑,其係在第(27)或(28)項中,適用於以含有2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑製劑取代含有奧美沙坦酯製劑之製劑,
(34)一種臭味防止方法,其係在第(29)或(30)項中,適用於以含有2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑製劑取代含有奧美沙坦酯製劑之臭味防止方法等。
藉由使用本發明的含有臭味吸附劑之包裝材,可提供一種當取出製劑時幾乎感覺不到臭味之包裝體。
本發明的包裝材係含有臭味吸附劑。使用本發明的包裝材之包裝體,係可吸附由製劑產生之臭味。
可使用於本發明的臭味吸附劑,例如合成沸石、矽膠、氧化鋁、活性碳等物理吸附劑、以有機酸為基礎之複合化學除臭劑(大姆修,Daimushen)般可與臭味物質進行化學吸附之化學吸附劑等,宜為合成沸石、尤宜疏水性沸石,特宜為高矽沸石。緣由於對臭味物質的吸附速度及吸附特性,亦可併用物理吸附劑和化學吸附劑。
合成沸石係依據相異的分子大小而用於分離物質的多孔質之粒狀物質,具有均勻的細孔之結構,吸附進入細孔空洞的小分子,以進行一種分篩作用。本發明中的吸附孔徑宜為0.3nm~1nm。細孔徑約為0.3nm、0.4nm、0.5nm、1nm的合成沸石分別稱為合成沸石3A、合成沸石4A、合成沸石5A、合成沸石13X。其中,尤宜細孔徑約為1nm的合成沸石13X。
合成沸石的平均粒徑無特別限定,係可完成本發明的
目的即可,例如宜為10μm左右之粒徑。且合成沸石之吸附特性係相關於細孔徑,為提高臭味吸附特性,藉著使合成沸石的粉末更細,可實際地增加表面積,並增加細孔數。
疏水性沸石係指施予疏水處理之合成沸石。合成沸石係具有吸附臭味和吸濕能力,因吸濕愈多則臭味的吸附性能降低,故尤宜經疏水處理以抑制吸濕能力之合成沸石。使合成沸石進行疏水處理之方法,例如使界面活性劑吸附於沸石之方法、或使矽烷化劑與沸石表面的羥基反應之方法等表面修飾方法或進行脫鋁處理之方法等。
高矽沸石係指使合成沸石的結晶架構內之鋁原子經過脫鋁處理而減少,提高二氧化矽/氧化鋁比(SiO2
/Al2
O3
比)之合成沸石。藉由脫鋁處理,可使合成沸石失去對水等極性物質之親和性,而更強地吸附臭味物質等非極性物質。其中,尤宜二氧化矽/氧化鋁比為5以上之高矽沸石。該類高矽沸石,例如可使用聯合昭和公司製的ABSCENT、東曹公司製的HSZ系列等市售品。
本發明的包裝材係可使用熱可塑性樹脂等樹脂類、紙類、纖維類、金屬類、各種塗料、各種黏附劑等,宜為熱可塑性樹脂。
熱可塑性樹脂係無特別的限制,可使用既知者,例如聚氯乙烯(PVC)、無延展聚丙烯(CPP)、聚丙烯(PP)、聚偏二氯乙烯(PVDC)、聚三氟化氯乙烯(PCTFE)、環狀烯烴共聚物(COC)、聚乙烯(PE)、聚碳酸酯(PC)、聚醯胺(PA)、乙烯-醋酸乙烯酯共聚物(EVA)、乙烯-甲基丙烯
酸酯共聚物、聚苯乙烯(PS)、聚酯(PET)、聚丙烯酸(PAA)等,宜為聚氯乙烯、無延展聚丙烯、聚丙烯、聚偏二氯乙烯、聚三氟化氯乙烯或環狀烯烴共聚物。本發明中,可單獨使用這些物質,亦可組合2種以上而使用。
本發明的包裝材係不限於單層者,亦可為使多層貼合之多層薄膜。多層薄膜之種類、量、厚度及層數,係無特別限制,只要完成本發明的目的即可,可廣泛地使用,因應用途而適當地選擇。
如第1圖所示般,本發明的多層薄膜1係具有作為內層的含臭味吸附劑之吸附層2,和作為外層的防止水分和氧等由外氣進入之基材層(障蔽層)3。
使用於吸附層之樹脂無特別的限制,使用者可適當地選擇,惟宜為高熔融流動率、低熔點(低軟化點),且低溫收縮性優異之樹脂。若為高熔融流動率樹脂,即使因添加吸附劑而降低熔融流動率,仍可維持一定程度的流動特性。若為低熔點,則樹脂於低溫下軟化,可於低溫擠壓,亦可預防發泡。若為低溫收縮性優異之樹脂,即使添加吸附劑亦易於以擠壓成形機進行擠壓成形。其中,尤宜熔融流動率為10以上又低熔點,且低溫收縮性優異之樹脂。
由此觀點,使用於吸附層之樹脂例如低密度聚乙烯(LDPE)、直鏈狀低密度聚乙烯(LLDPE)、聚丙烯(PP),各種共聚物(共聚物)例如離子鍵聚合物(例如乙烯丙烯酸共聚物的鹽)、乙烯丙烯酸共聚物(EAA)、乙烯甲基丙烯酸共聚物(EMAA)、乙烯醋酸乙烯酯共聚物(EVA)、乙
烯丙烯酸甲酯共聚物(EMA)、乙烯甲基丙烯酸甲酯共聚物(EMMA)等,宜為低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯,尤宜低密度聚乙烯。本發明中,可單獨使用這些物質,亦可組合2種以上而使用。
吸附層中,可依需求摻合其他顏料。上述臭味吸附劑之外的顏料,係可使用不特別具有吸濕性能或氣體吸附性能之顏料,若含有具機能之顏料,即具備各種複合的效果。該類顏料例如合成沸石、氯化鈣、氧化鈣、碳酸鈣、氧化鈦、氧化鋅、氧化鋯、氧化鋁、二氧化矽、雲母、滑石、碳、活性碳等,宜為合成沸石。
吸附層中,臭味吸附劑之含率例如為5~70重量%,宜為10~60重量%。除臭味吸附劑之外,亦含有其他顏料時,總顏料之含率例如為30~70重量%,宜為45~65重量%。
吸附層之膜厚度係無特別的限制,惟可完成本發明的目的即可,例如10μm~200μm,宜為30μm~100μm。
使用於基材層的樹脂係可阻隔來自外部的水分和氧等進入之樹脂即可,無特別的限制可使用既知者,例如聚氯乙烯、無延展聚丙烯、聚丙烯、聚偏二氯乙烯、聚三氟化氯乙烯、環狀烯烴共聚物、聚乙烯、聚碳酸酯、聚醯胺、乙烯-醋酸乙烯酯共聚物、乙烯甲基丙烯酸酯共聚物、聚苯乙烯、聚酯、聚丙烯酸等,宜為聚氯乙烯、無延展聚丙烯、聚丙烯、聚偏二氯乙烯、聚對苯二甲酸乙二醇酯,尤宜聚氯乙烯。本發明中,可單獨使用這些物質,亦可組合2種
以上而使用。
基材層的厚度係無特別的限制,可完成本發明的目的即可,例如20μm~400μm,宜為50μm~300μm。
吸附層和基材層之間更可含有黏附層。黏附層例如低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯等,宜為低密度聚乙烯。本發明中,可單獨使用這些物質,亦可組合2種以上而使用。
使吸附層和基材層黏合之方法,例如擠壓層壓、乾層壓、濕層壓、熱層壓、砂層壓等,宜為乾層壓或砂層壓。擠壓層壓係指使熔融樹脂由T模頭薄薄地流於基材上,進行輥壓壓延而層積之方法。乾層壓係指將基材與預先成形的熱可塑性樹脂薄膜等相黏合方法中,將黏附劑塗布於基材後,於加熱乾燥爐中使黏附劑乾燥後將薄膜重疊,進行輥壓壓延之方法。濕層壓乃與乾層壓相異,係指不使黏附劑乾燥而使基材與薄膜黏合之方法。熱層壓係指使預先成形的熱可塑性樹脂薄膜重疊於基材,通過熱輥間而加熱壓延之方法。砂層壓係指抽出2個基材,由T模頭擠出熔融樹脂,流入兩基材之間,進行輥壓壓延而黏附之方法。
製得的多層薄膜之厚度係無特別的限制,可完成本發明的目的即可,例如30μm~500μm,宜為100μm~400μm。
如第2圖所示,在本發明的其他多層薄膜1中,吸層2係可在與基材層3接觸之主吸附層2a側更含有外層4,亦可在與基材層3相對之主吸附層2a側更含有密封膠層5。為了夾住主要吸附臭味之主吸附層,亦可含有輔助吸附
臭味之副吸附層。吸附層係由主吸附層和副吸附層而形成時,主吸附層中吸附劑之含率宜多於副吸附層中的含率。藉此,可提升吸附之效率。
密封膠層例如低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯等,宜為直鏈狀低密度聚乙烯。本發明中,可單獨使用這些物質,亦可組合2種以上而使用。
外層例如低密度聚乙烯、直鏈狀低密度聚乙烯、聚丙烯等,宜為直鏈狀低密度聚乙烯。本發明中,可單獨使用這些物質,亦可組合2種以上而使用。
吸附層係以吹塑薄膜法、T模頭法、共擠壓等使樹脂和吸附劑形成薄膜狀或薄片狀,尤宜藉由吹塑薄膜法所形成之多層薄膜。又,多層吹塑薄膜法係指以複數的擠壓機將熔融的樹脂擠壓成管狀,將空氣送至其中使之膨脹,製造多層薄膜之方法。吸附層之結構,宜為由外層/主吸附層/密封膠層所形成2種3層或3種3層。
使用本發明的包裝材而製作壓泡包裝或泡罩包裝,可包裝製劑。如第3圖所示般,本發明的壓泡包裝8係由收藏製劑7的含有袋部位之多層薄膜1(附袋式薄片)和用以密封袋部位之蓋材6而構成。附袋式薄片係具有複數個收藏製劑7之凹狀袋部位,將製劑7收藏於袋部位。
包裝於壓泡包裝或泡罩包裝之製劑,例如錠劑、膠囊劑、粉劑、細粒劑、顆粒劑、片劑等,宜為錠劑。
在壓泡包裝或泡罩包裝中,宜於與包裝材的製劑接觸之側含有密封膠層。藉由在多層薄膜的最內層含有密封膠
層,密封膠層則成為與蓋材料熱封之層,且可預防製劑與吸附層直接接觸。
蓋材料例如鋁箔、鋁箔和塑膠薄膜之層壓薄膜等。
本發明中的壓泡包裝或泡罩包裝之製作方法,係可使用如「醫藥品-食品包裝之設計、表示、材料規格、包裝工程之品質確保(技術資訊協會,2005年9月1日發刊)」刊物中記載之一般方法而製造,無特別的限制。
本發明中,含於製劑的有效成分係為含有臭味之藥物即可,不受限於其結構、程度,例如奧美沙坦酯、2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑、L-半胱胺酸、DL-甲硫基丁胺酸、布西拉明(Bucillamine)、甲基硫僅氯化硫鎓、鹽酸乙基半胱胺酸、鹽酸卡巴西林(Bacampicillin Hydrochloridel)、頭孢子菌素劑、甲苯礦酸舒米西林(Sultamicillin tosilate)、雙氯非那胺(Diclofenamide)、雷尼替定(Ranitidine)、啡莫替定(Famotidine)、尼薩替定(Nizatidine)等含硫化合物、奧美沙坦酯、吲哚心安(Dindolol)、丙戊酸鈉、鹽酸乙肼苯酞(Todralazine Hydrochloride)、鹽酸甲苯派丙酮、三甲環二酮、柳氮磺吡啶(Salazosulfapyridine)、氟比洛芬(Flurbiprofen)、中藥、草藥等有特殊臭味之藥物,宜為奧美沙坦酯或2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑。且奧美沙坦酯係有效於高血壓症或高血壓症引發的疾病(更具體而言,高血壓症、心臟疾病[狹心症、心肌梗塞、心律不整、心臟不
全或心臟肥大]、腎臟疾病[糖尿病性腎疾病、腎小球腎炎或腎硬化症]或腦血管性疾病[腦梗塞或腦出血])之預防或治療,可依據專利許可第2082519號公報(美國專利第5,616,599號公報)等記載之方法而易於製造。2-胺基-5-異丁基-4-{2-[5-(N,N’-雙((S)-1-乙氧羰基)乙基)膦醯胺]呋喃基}噻唑,係可依據國際公開第01/47935號手冊等記載之方法而易於製造。
又,本發明的製劑亦可依需求含有其他有效成分。該有效成分例如三氯甲苯噻(Trichloromethiazide)、氫氯苯噻(Hydrochlorothiazide)、苄基氫氯苯噻(Benzylhydrochlorothiazide)等利尿劑;阿折迪平(Azelnidipine)、脈優錠(Amlodipine)、貝尼迪平(Benidipine)、寜安錠(Nitrendipine)、瑪尼迪平(Manidipine)、尼卡迪平(Nicardipine)、尼菲迪平(Nifedipine)、西尼迪平(Cilnidipine)、愛尼迪平(Efonidipine)、巴尼迪平(Barnidipine)、順壓樂錠(Felodipine)等鈣阻斷劑;愛妥糖(Pioglitazone)、梵帝美(Rosiglitazone)、利格列酮(Rivoglitazone)、MCC-555、NN-2344、BMS-298585、AZ-242、LY-519818、TAK-559等胰島素阻抗性改良劑;普伐史達丁(Pravastatin)、喜克脂錠(Simvastatin)、立普妥錠(Atorvastatin)、羅思伐史達丁(Rosuvastatin)、薛利伐史達丁(Cerivastatin)、比他伐史達丁(Pitavastatin)、益脂可錠(Fluvastatin)等HMG-CoA還原酶抑制劑;SMP-797、派其米貝(Pactimibe)等ACAT抑制劑等,惟不受限於此。這些有效成分之量係無特別的限制,採用一般用於製劑之量即可。
以下以實施例等更詳細地說明本發明,惟本發明不受限於此。
相對於50重量份的高矽沸石(商品名:ABSCENTS3000聯合昭和公司製),使50重量份LDPE捏和且調整成顆粒狀樹脂,以此為主膠料(MB1)。
依據多層吹塑薄膜法,製作以下的2種3層薄膜。將MB1和基礎樹脂的LDPE以2:3之比例摻合,使其吸附劑含量為20重量%而使用,於外層及密封膠層只使用LLDPE,製作2種3層的吸附層,使各層的膜厚度為外層/主吸附層/密封膠層=10μm/60μm/10μm,以此為吸附層之樹脂。
使用砂層壓法以LDPE為黏附層,層積上述吸附薄膜的外層側與厚度200μm之聚氯乙烯(住友貝可萊特公司製),製作壓泡包裝用多層薄膜。
壓泡包裝係使用CKD公司製M2型而製作。壓泡包裝之材料係具有臭味吸附功能的上述多層薄膜,及作為蓋材料的厚度17μm之鋁箔(東洋鋁製),填充成每一片壓泡包裝含有10錠的奧美沙坦酯(奧美德克(註冊商標)20mg
錠)之製劑。
無延展聚丙烯的壓泡包裝係使用CKD公司製M2型而製作。壓泡包裝之材料係厚度250μm的無延展聚丙烯(住友貝可萊特公司製),及作為蓋材料的厚度17μm之鋁箔(東洋鋁製),填充成每一片壓泡包裝含有10錠的奧美沙坦酯之製劑(奧美德克(註冊商標)20mg錠)。
氣味測試器之測定係製作一具有可將取出錠劑時的臭味瞬間封住而測定之結構且內容量為72mL之專用容器而進行。使用該專用容器和氣味測試器(Portable Odor Meter FPO-1雙葉電子設備公司製),測定由壓泡包裝取出含有奧美沙坦酯的製劑時之臭味強度。將進行枕形密閉包裝之壓泡包裝和不進行枕形密閉包裝之壓泡包裝(開放)放入25℃的恆溫槽,1個月後開啟枕形密閉包裝,以氣味測試器來測定在專用容器內由壓泡包裝一次取出10錠時之臭味,其結果如表1所示。
由表1之結果可知,使用本發明的包裝材之壓泡包裝,明顯減少取出錠劑時之臭味。
將進行枕形密閉包裝之壓泡包裝或不進行枕形密閉包裝之壓泡包裝(開放),放入40℃及25℃的恆溫槽,6個月後開啟枕形密閉包裝,藉由官能試驗來進行由壓泡包裝取出錠劑時之臭味評估。其結果如表2所示。
評估方法0:無臭、0.5:非常稀少、1:稀少、2:弱、3:強評估值=品評員之總計值/品評員數(5)
由表2的結果可知,使用本發明的壓泡包裝,無論於任一保存狀態,均無取出製劑時之臭味,可長期維持臭味吸附功能。
依據本發明,可提供一種取出製劑時幾乎不感到臭味之醫藥品包裝體。
1‧‧‧多層薄膜
2‧‧‧吸附層
2a‧‧‧主吸附層
3‧‧‧基材層(障蔽層)
4‧‧‧外層
5‧‧‧密封膠層
6‧‧‧蓋材料
7‧‧‧製劑
8‧‧‧壓泡包裝
第1圖係本發明的多層薄膜之概略切面圖。
第2圖係本發明的多層薄膜之其他概略切面圖。
第3圖係本發明的壓泡包裝之概略切面圖。
Claims (13)
- 一種含有奧美沙坦酯(Olmesartan Medoxomil)製劑之臭味防止方法,其特徵為以多層薄膜包裝,該多層薄膜係具有含有臭味吸附劑之吸附層及含有聚氯乙烯之基材層的多層薄膜,其中該吸附層為具有主吸附層及在與基材層相對之側具有密封膠層之吸附層,該主吸附層含有含合成沸石作為臭味吸附劑之低密度聚乙烯,該密封膠層含有直鏈狀低密度聚乙烯。
- 如申請專利範圍第1項之含有奧美沙坦酯製劑之臭味防止方法,其中臭味吸附劑係合成沸石13X。
- 如申請專利範圍第1項之含有奧美沙坦酯製劑之臭味防止方法,其中臭味吸附劑係疏水性沸石。
- 如申請專利範圍第1項之含有奧美沙坦酯製劑之臭味防止方法,其中臭味吸附劑係對合成沸石13X施予疏水性處理之疏水性沸石。
- 如申請專利範圍第1項之含有奧美沙坦酯製劑之臭味防止方法,其中臭味吸附劑係高矽沸石。
- 如申請專利範圍第1項之含有奧美沙坦酯製劑之臭味防止方法,其中在吸附層和基材層之間更具有黏附層。
- 如申請專利範圍第6項之含有奧美沙坦酯製劑之臭味防止方法,其中黏附層係含有選自於低密度聚乙烯、直鏈狀低密度聚乙烯、及聚丙烯之化合物中的1種或2種以上。
- 如申請專利範圍第6項之含有奧美沙坦酯製劑之臭味防 止方法,其中黏附層係含有低密度聚乙烯。
- 如申請專利範圍第1項之含有奧美沙坦酯製劑之臭味防止方法,其中在與基材層接觸之吸附層側,更具有外層。
- 如申請專利範圍第9項之含有奧美沙坦酯製劑之臭味防止方法,其中外層係含有選自於低密度聚乙烯、直鏈狀低密度聚乙烯、及聚丙烯的化合物中之1種或2種以上。
- 如申請專利範圍第9項之含有奧美沙坦酯製劑之臭味防止方法,其中外層係含有直鏈狀低密度聚乙烯。
- 如申請專利範圍第1至11項中任一項之含有奧美沙坦酯製劑之臭味防止方法,其係以使用該多層薄膜之壓泡包裝或泡罩包裝來包裝。
- 如申請專利範圍第1至11項中任一項之含有奧美沙坦酯製劑之臭味防止方法,其係以於容器的附袋式薄片(pocket sheet)使用該多層薄膜之壓泡包裝或泡罩包裝來包裝。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006290033 | 2006-10-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201332594A TW201332594A (zh) | 2013-08-16 |
| TWI486183B true TWI486183B (zh) | 2015-06-01 |
Family
ID=39324511
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102113345A TWI486183B (zh) | 2006-10-25 | 2007-10-23 | 含有奧美沙坦酯製劑之臭味防止方法 |
| TW096139646A TWI402085B (zh) | 2006-10-25 | 2007-10-23 | 包裝材、壓泡包裝及錠劑 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096139646A TWI402085B (zh) | 2006-10-25 | 2007-10-23 | 包裝材、壓泡包裝及錠劑 |
Country Status (5)
| Country | Link |
|---|---|
| JP (2) | JP5241503B2 (zh) |
| KR (1) | KR101400653B1 (zh) |
| CN (1) | CN101528179B (zh) |
| TW (2) | TWI486183B (zh) |
| WO (1) | WO2008050714A1 (zh) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5500164B2 (ja) * | 2009-03-02 | 2014-05-21 | アステラス製薬株式会社 | 固形製剤の包装体 |
| EP2612827A4 (en) * | 2010-09-01 | 2014-10-22 | Astellas Pharma Inc | PACKAGING |
| TWI515113B (zh) * | 2010-09-01 | 2016-01-01 | 共同印刷股份有限公司 | 積層體、包裝容器及包裝體 |
| CN102152543A (zh) * | 2010-12-14 | 2011-08-17 | 郑勇 | 具有铝箔漫反射面金属光泽的聚乙烯镀铝薄膜 |
| JP5671397B2 (ja) * | 2011-03-30 | 2015-02-18 | 共同印刷株式会社 | 蓋材,包装容器及び包装体 |
| BR112014021667B1 (pt) * | 2012-03-01 | 2020-09-24 | Maruho Co., Ltd. | Embalagem de produtos medicinais |
| JP5849001B2 (ja) * | 2012-03-23 | 2016-01-27 | 第一三共株式会社 | Ptp又はブリスターパック用積層体、及びこれを用いて成形されたptp又はブリスターパック |
| JP6175425B2 (ja) * | 2012-03-23 | 2017-08-02 | 第一三共株式会社 | Ptp又はブリスターパック用積層体及びptp又はブリスターパック |
| JP6421404B2 (ja) * | 2013-05-31 | 2018-11-14 | 大日本印刷株式会社 | 医薬品包装体 |
| GB2538255B (en) | 2015-05-12 | 2020-02-26 | Innovia Films Ltd | Film for packaging |
| JP6927663B2 (ja) * | 2015-10-23 | 2021-09-01 | ニプロ株式会社 | 固形製剤包装体、及び固形製剤の臭い除去方法 |
| KR102503428B1 (ko) * | 2015-12-22 | 2023-02-24 | 한미약품 주식회사 | 두타스테라이드를 포함하는 경구용 연질 캡슐 제형용 포장재 |
| JP2018090298A (ja) * | 2016-12-05 | 2018-06-14 | 小林製薬株式会社 | ブリスターパッケージ |
| EP3381548A1 (en) * | 2017-03-31 | 2018-10-03 | Clariant International Ltd | Adsorbent and packaging material |
| JP6958030B2 (ja) * | 2017-07-04 | 2021-11-02 | 大日本印刷株式会社 | 低臭気積層体と該積層体からなる包装材料、及び該積層体の製造方法 |
| JP6992358B2 (ja) * | 2017-09-22 | 2022-01-13 | 大日本印刷株式会社 | 低臭気積層体と該積層体からなる包装材料、及び該積層体の製造方法 |
| KR102762081B1 (ko) | 2018-03-30 | 2025-02-03 | 다이니폰 인사츠 가부시키가이샤 | 악취 흡착 성형품 수지 조성물, 악취 흡착 성형품 및 포장 재료 |
| JP7143614B2 (ja) * | 2018-03-30 | 2022-09-29 | 大日本印刷株式会社 | 臭気吸着積層体及び臭気吸着性包装材料 |
| CN109467848A (zh) * | 2018-11-07 | 2019-03-15 | 温州莲华环保科技有限公司 | 一种高吸附功能膜及其制备方法 |
| JP7233213B2 (ja) * | 2018-12-13 | 2023-03-06 | 共同印刷株式会社 | ブリスターパック用積層体、それを用いたブリスターパック、及びブリスターパック包装体 |
| CN110589228A (zh) * | 2019-08-02 | 2019-12-20 | 中山火炬职业技术学院 | 一种异味固体的密封包装工艺 |
| JP7162363B2 (ja) * | 2020-09-29 | 2022-10-28 | Mics化学株式会社 | 積層フィルムおよび袋体 |
| WO2023043426A1 (en) | 2021-09-14 | 2023-03-23 | Dow Global Technologies Llc | Zeolite containing polyolefin films |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08197692A (ja) * | 1995-01-30 | 1996-08-06 | Dainippon Printing Co Ltd | ガスバリヤー積層材 |
| JP2006028496A (ja) * | 2004-06-18 | 2006-02-02 | Toyo Seikan Kaisha Ltd | 臭気捕捉用樹脂組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0624571B2 (ja) * | 1988-11-21 | 1994-04-06 | 明治製菓株式会社 | 医薬品包装容器 |
| SE469080B (sv) * | 1991-10-28 | 1993-05-10 | Eka Nobel Ab | Foerpackningsmaterial, foerfarande foer framstaellning av foerpackningsmaterial, anvaendning av hydrofob zeolit foer framstaellning av foerpackningsmaterial samt anvaendning av foerpackningsmaterial |
| JPH08104370A (ja) * | 1994-10-04 | 1996-04-23 | Kishimoto Akira | 調理食品包装容器 |
| US20040116025A1 (en) * | 2002-12-17 | 2004-06-17 | Gogins Mark A. | Air permeable garment and fabric with integral aerosol filtration |
| CN1271068C (zh) * | 2003-03-25 | 2006-08-23 | 上海医药工业研究院 | 一种奥美沙坦酯的制备方法 |
| JP4659523B2 (ja) * | 2005-04-26 | 2011-03-30 | 共同印刷株式会社 | ブリスター用フィルム及びブリスター用包装容器 |
| KR101314439B1 (ko) * | 2005-05-20 | 2013-10-07 | 다이이찌 산쿄 가부시키가이샤 | 덱스트로오스 함유 필름 코팅 제제 |
| WO2006123765A1 (ja) * | 2005-05-20 | 2006-11-23 | Daiichi Sankyo Company, Limited | フィルムコーティング製剤 |
-
2007
- 2007-10-22 WO PCT/JP2007/070539 patent/WO2008050714A1/ja not_active Ceased
- 2007-10-22 CN CN2007800395199A patent/CN101528179B/zh active Active
- 2007-10-22 KR KR1020097006803A patent/KR101400653B1/ko active Active
- 2007-10-22 JP JP2008540976A patent/JP5241503B2/ja active Active
- 2007-10-23 TW TW102113345A patent/TWI486183B/zh active
- 2007-10-23 TW TW096139646A patent/TWI402085B/zh active
-
2013
- 2013-02-12 JP JP2013024058A patent/JP5546072B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08197692A (ja) * | 1995-01-30 | 1996-08-06 | Dainippon Printing Co Ltd | ガスバリヤー積層材 |
| JP2006028496A (ja) * | 2004-06-18 | 2006-02-02 | Toyo Seikan Kaisha Ltd | 臭気捕捉用樹脂組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101528179B (zh) | 2013-06-26 |
| TW200824728A (en) | 2008-06-16 |
| WO2008050714A1 (fr) | 2008-05-02 |
| CN101528179A (zh) | 2009-09-09 |
| TWI402085B (zh) | 2013-07-21 |
| JP5241503B2 (ja) | 2013-07-17 |
| KR101400653B1 (ko) | 2014-05-27 |
| TW201332594A (zh) | 2013-08-16 |
| JPWO2008050714A1 (ja) | 2010-02-25 |
| KR20090074754A (ko) | 2009-07-07 |
| JP5546072B2 (ja) | 2014-07-09 |
| JP2013121535A (ja) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI486183B (zh) | 含有奧美沙坦酯製劑之臭味防止方法 | |
| JP6175425B2 (ja) | Ptp又はブリスターパック用積層体及びptp又はブリスターパック | |
| JP4659523B2 (ja) | ブリスター用フィルム及びブリスター用包装容器 | |
| CA2664380C (en) | Medicinal package | |
| JP5603854B2 (ja) | 酸素吸収プラスチック構造 | |
| US6113927A (en) | Package and packaging method for aqueous liquid materials | |
| JP6684718B2 (ja) | ブリスターパック用積層体、それを用いたブリスターパック、及びブリスターパック包装体、並びにその積層体の製造方法 | |
| EP2612827A1 (en) | Package | |
| KR101721180B1 (ko) | 포장재 및 그것을 사용하여 이루어지는 포장 구조 | |
| EP3312004B1 (en) | Laminate for use in blister pack, and blister pack using same | |
| JP6604947B2 (ja) | イージーピール性の包装袋 | |
| JP2014076852A (ja) | 薬剤包装用シート、および薬剤包装体 | |
| JP7252592B2 (ja) | 包装材 | |
| JP2021147086A (ja) | 包装体 | |
| MX352703B (es) | Paquete de producto medicinal. | |
| JP2020093480A (ja) | ブリスターパック用積層体、それを用いたブリスターパック、及びブリスターパック包装体 | |
| JP2001120642A (ja) | パップ剤の保存方法 |